International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Update

by · The Markets Daily

International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 808 shares, a drop of 89.7% from the August 15th total of 7,881 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 92,036 shares, the days-to-cover ratio is currently 0.0 days.

International Stem Cell Price Performance

ISCO remained flat at $0.36 during trading on Friday. The company’s stock had a trading volume of 28,587 shares, compared to its average volume of 29,057. The company has a market capitalization of $2.88 million and a PE ratio of -4.50. The company’s 50 day moving average price is $0.31 and its 200 day moving average price is $0.22. International Stem Cell has a 52-week low of $0.12 and a 52-week high of $0.54.

International Stem Cell (OTCMKTS:ISCO – Get Free Report) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $2.67 million for the quarter.

International Stem Cell Company Profile

(Get Free Report)

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.

See Also